Devic disease with favorable response to rituximab: report of a case

Authors

DOI:

https://doi.org/10.18537/RFCM.37.01.06

Keywords:

case reports, neuromyelitis optica, rituximab

Abstract

ABSTRACT

Devic's disease, is also called neuromyelitis optica, it is a demyelinating autoimmune entity of the central nervous system, it is uncommon and it compromises the optic nerves and the spinal cord, causing loss of visual acuity and motor impairment. A clinical case of a 25-year-old woman with signs of sudden myelopathy and amaurosis is presented. It is fulfilling criteria for neuromyelitis optica. The treatment with methylprednisolone boluses started without any improvement, and Rituximab was applied with an early favorable response. Rituximab belongs to the group of anti-CD20 monoclonal antibodies, it was an important option in the absence of response to the first line of treatment.

KEYWORDS: case reports, neuromyelitis optica, rituximab.

Downloads

Download data is not yet available.

Downloads

Published

2019-06-22

Issue

Vol. 37 No. 1 (2019): Revista de la Facultad de Ciencias Médicas de la Universidad de Cuenca

Section

Clinical Case

License

Copyright © Autors.

You are free to:

Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Under the following conditions:

Attribution — You must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licenser endorses you or your use.
  NonCommercial  — You may not use the material for commercial purposes.
  ShareAlike  — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.